W: decision granting a waiver in all age groups for all conditions or indications
Decision date
Decision
P/0136/2024: EMA decision of 6 May 2024 on the granting of a product specific waiver for clostridium botulinum neurotoxin type A (150 kD), free from complexing proteins (Xeomin, Bocouture), (EMEA-001039-PIP04-23)